Sinusitis - Pipeline Review, H2 2011

Global Markets Direct, September 2011, Pages: 52

Sinusitis - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Sinusitis - Pipeline Review, H2 2011', provides an overview of the Sinusitis therapeutic pipeline. This report provides information on the therapeutic development for Sinusitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Sinusitis. 'Sinusitis - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Sinusitis.
- A review of the Sinusitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Sinusitis pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Sinusitis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Sinusitis pipeline depth and focus of Sinusitis therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Sinusitis Overview
Therapeutics Development
An Overview of Pipeline Products for Sinusitis
Sinusitis Therapeutics under Development by Companies
Sinusitis Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Sinusitis Therapeutics - Products under Development by Companies
Sinusitis Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Sinusitis Therapeutics Development
GlaxoSmithKline plc
PARI Pharma GmbH
Manhattan Pharmaceuticals, Inc.
NovaBay Pharmaceuticals, Inc.
Accentia Biopharmaceuticals, Inc.
SCOLR Pharma, Inc.
Bionorica AG
Mayne Pharma Limited
Sinusitis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
SinuNase - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Phenylephrine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NVC-422 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ATV-02 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Levofloxacin vibrENT - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GSK685698 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
N-Chlorotaurine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Xolair - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lidocaine + Adrenaline - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pseudoephidrine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dornase Alfa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pulmozyme - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BNO 1016 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bacitracin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sinusitis Therapeutics – Drug Profile Updates
Sinusitis Therapeutics - Discontinued Products
Sinusitis - Featured News
Sep 12, 2011: NovaBay Pharmaceuticals Reports Positive Results In Sinus Infection Study
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Sinusitis, H2 2011
Products under Development for Sinusitis – Comparative Analysis, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Late Stage Development, H2 2011
Comparative Analysis by Mid Clinical Stage Development, H2 2011
Comparative Analysis by Early Clinical Stage Development, H2 2011
Comparative Analysis by Pre-Clinical Stage Development, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
GlaxoSmithKline plc, H2 2011
PARI Pharma GmbH, H2 2011
Manhattan Pharmaceuticals, Inc., H2 2011
NovaBay Pharmaceuticals, Inc., H2 2011
Accentia Biopharmaceuticals, Inc., H2 2011
SCOLR Pharma, Inc., H2 2011
Bionorica AG, H2 2011
Mayne Pharma Limited, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Sinusitis Therapeutics – Drug Profile Updates
Discontinued Products

List of Figures
Number of Products under Development for Sinusitis, H2 2011
Products under Development for Sinusitis – Comparative Analysis, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Late Stage Products, H2 2011
Mid Clinical Stage Products, H2 2011
Early Clinical Stage Products, H2 2011
Pre-Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Route of Administration, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011

Customers who bought this item also bought

• Pandemic Influenza – Pipeline Review, H1 2013
• Nausea – Pipeline Review, H1 2013
• Substance (Drug) Abuse – Pipeline Review, H1 2013
• Drug Addiction – Pipeline Review, H1 2013
• Smoking Cessation – Pipeline Review, H1 2013
• Brain Tumor – Pipeline Review, H1 2013
• Bone Disorders – Pipeline Review, H1 2013
• Ebola Viral Infections – Pipeline Review, H1 2013
• Liver Transplantation – Pipeline Review, H1 2013
• Essential Thrombocythemia – Pipeline Review, H1 2013